Overview

A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.
Phase:
Phase 3
Details
Lead Sponsor:
Glaxo Wellcome
Treatments:
Amprenavir
Lamivudine
Zidovudine